A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease

PURPOSE: This study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn's disease (CD). METHODS: A computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performed. Randomized controlled trials (rcts) or nonrandomized controlled trials (n-rcts) were included in this article to evaluate the role of ADA in the management of fistula in CD. The methodological index for nonrandomized studies (MINORS evaluation tools) was used to assess the quality of every study. RESULT: Overall, seven studies and 379 patients comforted to the inclusion criteria of this meta-analysis. The result showed that 36% (95% CI: 0.31–0.41) of patients with complete fistula closure and 31% (95% CI: 0.031–0.61) of patients with partial response were received in CD with ADA treatment. CONCLUSION: We concluded that ADA is effective and safe for the treatment of fistula in CD according to current evidence.